GrapheneDx
GrapheneDx develops handheld at-home diagnostic devices using graphene field effect transistor (GFET) biosensor technology to deliver lab-quality results in under five minutes. The Boston-based company, majority-owned by KKR-backed Sapphiros, serves consumers and point-of-care healthcare providers.
- Company typePrivate
- Founded2020
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What GrapheneDx does
GrapheneDx, Inc. is a Boston-based diagnostics company developing handheld at-home testing devices built on a graphene field effect transistor (GFET) biosensor platform. The core technology uses a one-atom-thick layer of carbon atoms arranged in a hexagonal lattice to detect disease biomarkers with high electron mobility, targeting lab-quality accuracy in under five minutes across a portfolio of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. The product system comprises a central handheld reader plus a portfolio of sample collection accessories designed for blood, urine, saliva, and stool, with multiplexing capability for concurrent analyte detection and minimal sample preparation. First commercial tests are focused on chlamydia and gonorrhea using non-invasive urine samples.
GrapheneDx operates as a Sapphiros Group Company, majority-owned by Sapphiros, a diagnostics platform formed in July 2021 by KKR's Health Care Strategic Growth strategy and former Smith & Nephew/Alere CEO Namal Nawana, with additional backing from Neoenta. Co-founded in 2020 by Mohammed Fotouhi, the company merged with Rite Taste, LLC that same year and relocated to Boston's Seaport district in September 2021 to support growth. Mike Musgnug was appointed CEO in September 2022 while also serving as EVP Strategy for Sapphiros.
The business model centers on hardware sales of diagnostic devices and associated test kits across two primary go-to-market motions: direct-to-consumer for at-home testing and sales-led distribution into point-of-care healthcare settings, leveraging Sapphiros's commercial organization and channel partner relationships. Commercial manufacturing is enabled through a June 2023 strategic partnership with General Graphene Corp, which supplies sheet-based CVD graphene at 100,000 square meters of annual capacity, combined with Sapphiros's extreme volume manufacturing (EVM) facility capable of 5 billion tests per year. Revenue has not commenced; the company is pre-commercial.
GrapheneDx firmographics
Firmographics- Name
- GrapheneDx
- Legal name
- GrapheneDx, Inc.
- Website
- https://graphenedx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GrapheneDx develops handheld at-home diagnostic devices using graphene field effect transistor (GFET) biosensor technology to deliver lab-quality results in under five minutes. The Boston-based company, majority-owned by KKR-backed Sapphiros, serves consumers and point-of-care healthcare providers.
- Ownership category
- akta.pro rank
GrapheneDx industry classification
Industry- Product category
- At-Home Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where GrapheneDx is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GrapheneDx business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Diagnostic Tests and Devices: Sale of handheld diagnostic devices and associated test kits for at-home and point-of-care use. Products include tests for sexually transmitted infections, respiratory disease, cardiac disease, concussion, and other conditions using various sample types.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
GrapheneDx product offering
Product offeringCore offering
GrapheneDx designs and sells handheld at-home diagnostic devices powered by a proprietary graphene field effect transistor (GFET) biosensor platform that delivers lab-quality diagnostic results in under five minutes. The platform supports multiple sample types (blood, urine, saliva, stool) via dedicated collection accessories and is being developed to detect a range of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. First commercial tests target STIs (chlamydia and gonorrhea) using non-invasive urine samples.
Product overview
GrapheneDx offers a unified at-home diagnostic testing platform centered around a handheld graphene field effect transistor (GFET) biosensor device. The platform supports multiple sample collection accessories (blood, urine, saliva, and stool collection devices) that work with the core handheld device to enable rapid, lab-quality diagnostic testing for various disease states including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. Results are delivered in under five minutes with minimal or no sample preparation required.
Differentiator
Problem solved
Functional benefit
Products and services
- GrapheneDx Handheld Diagnostic Device A handheld at-home testing device utilizing graphene field effect transistor (GFET) biosensor technology that provides lab-quality diagnostic results in under five minutes for various disease states and sample types. Designed for use by individual consumers at home and by medical professionals at point-of-care settings.
- Blood Collection Device Sample collection device designed for blood-based diagnostic testing with the GrapheneDx handheld diagnostic platform.
- Urine Collection Device Sample collection device designed for urine-based diagnostic testing with the GrapheneDx platform, featuring a front tab for collection and a back tab designed as a reservoir for user guidance.
- Saliva Collection Device Sample collection device designed for saliva-based diagnostic testing with the GrapheneDx platform.
- Stool Collection Device Sample collection device designed for fecal/stool sample diagnostic testing with the GrapheneDx platform.
Quantifiable outcome
- Results in less than 5 minutes
- +2 more outcomes
Companies that use GrapheneDx
Customer profileSegments3 records
Ideal customer profiles2 records
GrapheneDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
GrapheneDx partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- General Graphene CorporationcoreStrategic partnership to industrialize graphene-based biosensors. General Graphene Corp serves as GrapheneDx's preferred supplier of sheet-based chemical vapor deposition (CVD) graphene delivered in roll-to-roll format for use in Sapphiros's extreme volume manufacturing facility. General Graphene has existing annual capacity of 100,000 square meters of sheet graphene.
- SapphiroscoreSapphiros is a platform company dedicated to building the next generation of consumer diagnostic technologies, backed by KKR and Neoenta. Sapphiros contributes expertise in extreme volume manufacturing (EVM) with capacity of 5 billion tests per year, including printed electronics and printed battery technology. GrapheneDx is a Sapphiros Group Company.
- Sapphiros (Management)coreMike Musgnug joined Sapphiros as EVP Strategy and CEO of GrapheneDx, leading strategy development and business development for Sapphiros in addition to leading the GrapheneDx organization. Sapphiros provides operational support and resources to GrapheneDx.
- BiocrucibleminorBritish molecular diagnostics company acquired by Sapphiros alongside GrapheneDx. Applies novel isothermal amplification methods to disposable and point-of-care diagnostic technologies. Part of the same cohort of innovative diagnostics companies under Sapphiros platform.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
GrapheneDx competitors and assessment
Company assessmentDirect peers
- Cue Health: Cue Health markets a connected at-home molecular diagnostic platform (respiratory, sexual health) directly to consumers — the same direct-to-consumer, handheld, rapid-result positioning GrapheneDx is targeting with its GFET device.
- Visby Medical: Visby Medical develops handheld PCR-based diagnostic devices for at-home and point-of-care STI and infectious disease testing — closely comparable in form factor, target use cases, and consumer/POC GTM.
- Lucira Health: Lucira (acquired by Pfizer) pioneered a single-use at-home molecular COVID test and was pivoting into broader respiratory/STI testing — a direct adjacency to GrapheneDx's at-home multiplex device strategy.
Broad incumbents
- Cepheid (Danaher): Cepheid is the established leader in molecular point-of-care diagnostics (GeneXpert); CEO Musgnug previously held commercial roles there, and the company anchors the POC molecular category GrapheneDx is targeting.
- Abbott Diagnostics: Abbott owns BinaxNOW, the Alere rapid-diagnostics franchise (acquired for $8B with Nawana at the helm), and the ID NOW platform — a broad incumbent in both at-home lateral-flow and POC molecular diagnostics.
- Becton Dickinson (BD): BD is a global diagnostics and life sciences incumbent with a deep portfolio in molecular, rapid antigen, and POC testing, providing scale distribution and a relevant comparable for handheld diagnostic commercialization.
- QuidelOrtho: QuidelOrtho (formed via Quidel-Ortho merger) is a leading rapid-diagnostics player (Sofia, QuickVue) with strong at-home and POC presence in respiratory and infectious disease — directly comparable to GrapheneDx's initial target indications.
Emerging players
- Mammoth Biosciences: Mammoth is developing CRISPR-based molecular diagnostic platforms for at-home and POC use — an emerging peer competing on novel detection chemistry, broadly comparable in ambition though different in core technology.
- Sherlock Biosciences: Sherlock is commercializing CRISPR-based and synthetic biology molecular diagnostics (including at-home applications) — an emerging competitor in next-generation molecular detection adjacent to GrapheneDx's GFET platform.
- T2 Biosystems: T2 Biosystems develops rapid molecular diagnostic panels (sepsis, Candida) using a non-PCR detection technology for hospital use — an adjacent emerging player showing how novel detection chemistries can reach clinical scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GrapheneDx social profiles
Digital presenceGrapheneDx compliance and trust
Trust signalCompliance2 records
GrapheneDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
GrapheneDx leadership team
Management profileNumber of profiles
Profiles8 records
GrapheneDx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GrapheneDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GrapheneDx
What does GrapheneDx do?
GrapheneDx designs and sells handheld at-home diagnostic devices powered by a proprietary graphene field effect transistor (GFET) biosensor platform that delivers lab-quality diagnostic results in under five minutes. The platform supports multiple sample types (blood, urine, saliva, stool) via dedicated collection accessories and is being developed to detect a range of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. First commercial tests target STIs (chlamydia and gonorrhea) using non-invasive urine samples.
Is GrapheneDx a public or private company?
GrapheneDx is a private company. It is classified as private equity controlled and is currently operating.
When was GrapheneDx founded?
GrapheneDx was founded in 2020. It employs 11 to 50 people.
Where is GrapheneDx based?
GrapheneDx is headquartered in Boston, United States, in the North America region.
How does GrapheneDx make money?
One revenue line is on record: diagnostic Tests and Devices.
Who are GrapheneDx's main competitors?
Direct peers on record are Cue Health, Visby Medical and Lucira Health. Broad incumbents are Cepheid (Danaher), Abbott Diagnostics, Becton Dickinson (BD) and QuidelOrtho. Emerging players are Mammoth Biosciences, Sherlock Biosciences and T2 Biosystems.
Does GrapheneDx have an API?
No public API is recorded for GrapheneDx.
What industry is GrapheneDx in?
GrapheneDx's product category is At-Home Diagnostic Devices. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334510 and its SIC code is 3845.